Covid-19 product gross sales are anticipated to dry up.
Pfizer mentioned Friday it’s reducing its steering for the 12 months by $9 billion attributable to modifications in anticipated gross sales of its Covid-19 vaccine and therapy Paxlovid.
Pfizer lowered its steering to between $58 billion and $61 billion from between $67 billion and $70 billion. The corporate is slashing its steering for Paxlovid by $7 billion and the vaccine by roughly $2 billion. Pfizer beforehand mentioned it anticipated $8 billion in Paxlovid gross sales this 12 months and $13.5 billion from the vaccine.
